| |
Wednesday, March 26, 2025 | 12pm ET / 9am PT Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today. 
|
|
Today’s Big NewsMar 21, 2025 |
|
Thursday, March 27, 2025 | 11am ET / 8am PT This webinar will explore the growing need for process intensification in bioprocessing as a crucial step toward enhancing efficiency and sustainability. Join us to gain valuable insights into overcoming challenges related to bioprocess scale-up, including the adaptation of novel bioreactors, media formulations, and cell culture practices. Register now. 
|
|
| By Fraiser Kansteiner Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts-based drugmaker has a fresh FDA approval to support its thesis. |
|
|
|
By Angus Liu Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shortfalls in the drug's label, leaving more to be desired—and potential room for improvement for rival Apellis. |
By Fraiser Kansteiner The FDA approved Tremfya as an induction therapy in adults with moderately to severely active Crohn’s disease, making the drug the first IL-23 inhibitor cleared for both subcutaneous and intravenous treatment of the inflammatory bowel disease in the U.S. |
By Gabrielle Masson As the U.S. cuts federal research funding and infrastructure, European countries are strategizing ways to attract top scientific talent, with the Netherlands government setting up a fund designed to do just that. |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.  
|
|
By Conor Hale At its GTC conference in San Jose, Nvidia outlined collaborations with several medtech developers, including GE HealthCare, to advance the tech behind robotic surgery and digital imaging. |
By Angus Liu The FDA has once again issued a complete response letter to Hengrui and Elevar’s applications for camrelizumab and rivoceranib in first-line liver cancer, with manufacturing again being the issue. |
By Nick Paul Taylor AstraZeneca has shown its commitment to China amid investigations into its executives and activities, outlining plans to establish a global strategic R&D center in Beijing as part of a $2.5 billion investment in the city. |
By Kevin Dunleavy Johnson & Johnson will invest $55 billion in the U.S. over the next four years. The announcement comes a month after Eli Lilly revealed a similar U.S.-focused plan to boost its manufacturing base. |
By James Waldron Vaxart has laid off 10% of its staff after the U.S. government unexpectedly ordered the biotech stop work on a trial of its COVID-19 vaccine pill. |
By Andrea Park Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and people of color in movies and TV. Now, Eli Lilly is hoping to spark a similar change in how common diseases are represented on-screen, too. |
By Darren Incorvaia,Zoey Becker About three months after leaving her post as the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., has found a new venture as a member of Recursion’s board of directors. |
By Gabrielle Masson Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 million IPO. |
By Andrea Park A Big Pharma may seem like an incongruous choice of sponsor for a global music competition, but a new initiative from Novartis suggests that its work actually has plenty in common with the 2025 Eurovision Song Contest. |
By Dave Muoio The former physician-lawmaker was an influential player in congressional health policy during his 20-plus years in the House. The White House has not yet named its next choice for the position after pulling the nomination of Dave Weldon, M.D., last week. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore the potential impacts of this year's sizable patent cliff on the pharma industry at large. |
|
|---|
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
